Takeda Pay Cuts Part Of Fallout From CASE-J Affair
This article was originally published in PharmAsia News
Takeda Pharmaceutical Co. Ltd. says it has already taken, and will continue to implement, a series of measures to avoid a repeat of partially inappropriate promotional activities for a blockbuster antihypertensive drug that were based on investigator-initiated sponsored research (IISR).
You may also be interested in...
Amgen has an open road for its Mvasi bevacizumab biosimilar after Genentech’s appeal to enjoin sales, over a notice of commercial marketing technicality, was denied. The US firm continues to weigh up patent-infringement proceedings in separate actions.
Coronavirus-induced stockpiling and advanced prescribing of medicines has resulted in generics companies across the world registering unprecedented growth during the first quarter of 2020. However, many companies predict sales will level off again in the next quarter and beyond. And as demand fluctuates following the COVID-19 outbreak, companies have started taking precautionary measures to avoid supply-chain disruptions.
Coronavirus Update: Regeneron Races Into Phase III Trial Of Antibodies To Block Coronavirus Infection
Regeneron and NIAID kick off a Phase III prevention trial for antibody cocktail REGN-COV2.